Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-highest quintile among peers.
Fidelity Advisor Biotechnology M FBTTX
- NAV / 1-Day Return 27.04 / +0.41 %
- Total Assets 1.6 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.290%
- Distribution Fee Level Average
- Share Class Type Front Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment —
- Status Open
- TTM Yield 0.91%
- Turnover 78%
USD | NAV as of May 07, 2024 | 1-Day Return as of May 07, 2024, 10:22 PM GMT+0
Morningstar’s Analysis FBTTX
Will FBTTX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 63.2
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
AbbVie Inc | 24.05 | 434.9 Mil | Healthcare |
Amgen Inc | 9.45 | 170.9 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 7.82 | 141.3 Mil | Healthcare |
Ascendis Pharma A/S ADR | 3.97 | 71.8 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 3.64 | 65.8 Mil | Healthcare |
Alnylam Pharmaceuticals Inc | 3.31 | 59.9 Mil | Healthcare |
Viking Therapeutics Inc | 3.25 | 58.8 Mil | Healthcare |
Cytokinetics Inc | 3.12 | 56.5 Mil | Healthcare |
argenx SE ADR | 2.28 | 41.3 Mil | Healthcare |
Vaxcyte Inc Ordinary Shares | 2.26 | 40.9 Mil | Healthcare |